Analyst firms · Leerink Partners · LLY

Leerink Partners LLY price target and rating history

Eli Lilly and Company (LLY) · Health Care

Leerink Partners rates Eli Lilly and Company (LLY) Outperform with a $1,104 price target, as of its latest action on Nov 10, 2025. It has published 3 rating actions on LLY since May 2022, including 1 upgrade and 1 downgrade. Across 8 firms with a LLY price target in the last 12 months, the median target is $1,250.

Current rating
Outperform
Price target
$1,104
Median target, all firms
$1,250
Actions on LLY
3

Leerink Partners price target on LLY

$1,104$723$3412023202420252026
Leerink Partners price target on LLY, each point a stated target, May 2022 to November 2025.

Every Leerink Partners rating on LLY

How other firms rate LLY

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BerenbergBuy$1,400Sep 15, 2026
HSBCReduce$850Mar 17, 2026
RBC Capital MarketsOutperform$1,250Feb 25, 2026
BarclaysOverweight$1,350Feb 20, 2026
UBSBuy$1,250Jan 7, 2026
DaiwaBuy$1,230Dec 16, 2025
Goldman SachsBuy$1,145Dec 15, 2025
BofA SecuritiesBuy$1,268Dec 15, 2025

Questions about Leerink Partners and LLY

What is Leerink Partners's price target for LLY?
Leerink Partners's latest stated price target for Eli Lilly and Company (LLY) is $1,104, from its action on Nov 10, 2025.
What is Leerink Partners's rating on LLY?
Leerink Partners rates LLY Outperform, a bullish rating, as of Nov 10, 2025.
When did Leerink Partners last change its view on LLY?
On Nov 10, 2025, Leerink Partners upgrades to Outperform from Market Perform, price target $1,104.
How does Leerink Partners's LLY target compare with other analysts?
Across 8 firms with a LLY price target in the last 12 months, the median target is $1,250.

More LLY rating histories

All Leerink Partners ratingsLLY news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.